PLXP · Plx Pharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $1.46M | $0 | $1.17M | - | $3.91M | - | - | - | - | - |
| Gross Profit | ($1.07M) | ($337.0K) | $914.0K | - | $2.70M | - | - | - | - | - |
| R&D | $623.0K | $556.0K | $654.0K | - | $1.55M | $982.7K | $959.5K | - | $1.21M | $1.39M |
| SG&A | $9.14M | $13.64M | $18.46M | - | $1.98M | $5.50M | $2.64M | - | $1.98M | $2.21M |
| Total Operating Expenses | $9.77M | $14.20M | $19.11M | - | $12.57M | $6.48M | $3.60M | - | $3.19M | $3.60M |
| D&A | - | - | $30.0K | - | - | - | $26.6K | - | - | - |
| Operating Income | ($10.84M) | ($14.54M) | ($18.20M) | - | ($9.86M) | ($6.48M) | ($3.60M) | - | ($3.19M) | ($3.57M) |
| Interest Expense | - | - | - | - | - | - | - | - | $72.7K | $104.7K |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | - | - | - | - |
| Net Income | ($8.50M) | ($11.86M) | ($10.79M) | - | ($21.64M) | ($16.50M) | ($11.54M) | - | ($3.13M) | ($5.60M) |
| EPS - Basic | ($0.30) | ($0.43) | ($0.39) | - | - | - | ($0.73) | - | ($0.40) | ($0.66) |
| EPS - Diluted | - | - | - | - | - | - | ($0.73) | - | ($0.40) | ($0.66) |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.83M | $35.73M | $52.50M | $69.39M | $82.55M | $80.17M | $84.42M | $22.45M | $9.09M | $13.26M |
| Accounts Receivable | $139.0K | $490.0K | $698.0K | $634.0K | $3.25M | - | - | - | - | - |
| Inventory | $3.18M | $3.88M | $3.84M | $2.46M | $2.19M | $1.26M | - | $100.0K | $143.4K | $100.0K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $30.22M | $41.48M | $57.75M | $73.48M | $88.61M | $82.01M | $84.87M | $22.99M | $9.62M | $13.76M |
| Total Assets | $33.22M | $44.54M | $60.86M | $76.64M | $91.84M | $85.31M | $88.32M | $26.62M | $13.35M | $17.78M |
| Current Liabilities | $6.31M | $9.07M | $13.23M | $11.88M | $7.41M | $3.06M | $1.41M | $3.54M | $3.81M | $5.17M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $7.02M | $12.04M | $18.88M | $24.96M | $44.93M | $29.18M | $22.28M | $16.16M | $11.69M | $12.76M |
| Stockholders' Equity | $10.19M | $16.49M | $25.97M | $35.67M | $30.89M | $40.12M | $44.66M | ($10.93M) | ($19.72M) | ($16.38M) |
| Retained Earnings | ($179.41M) | ($170.92M) | ($159.06M) | ($148.27M) | ($151.84M) | ($130.19M) | ($113.69M) | ($102.15M) | ($94.17M) | ($91.04M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($16.89M) | - | - | - | ($4.28M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $66.26M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.6% | -26.6% | -17.7% | - | -23.6% | -19.3% | -13.1% | - | -23.4% | -31.5% |
| Return on equity | -83.4% | -71.9% | -41.5% | - | -70.1% | -41.1% | -25.8% | - | 15.9% | 34.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.79 | 4.57 | 4.36 | 6.19 | 11.97 | 26.76 | 60.22 | 6.49 | 2.52 | 2.66 |
| Quick ratio | 4.28 | 4.15 | 4.07 | 5.98 | 11.67 | 26.35 | 60.22 | 6.46 | 2.49 | 2.64 |
| Cash ratio | 4.09 | 3.94 | 3.97 | 5.84 | 11.15 | 26.16 | 59.91 | 6.34 | 2.38 | 2.56 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -43.9x | -34.1x |
| Equity multiplier | 3.26 | 2.70 | 2.34 | 2.15 | 2.97 | 2.13 | 1.98 | -2.43 | -0.68 | -1.09 |
| Liabilities / Assets | 0.21 | 0.27 | 0.31 | 0.33 | 0.49 | 0.34 | 0.25 | 0.61 | 0.88 | 0.72 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.46 | 0.00 | 0.30 | - | 1.79 | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 795d | - | 1199d | - | 204d | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -9.9% | -124.3% | -406.0% | - | -209.3% | -81.3% | -19.7% | - | 13.3% | 7.1% |
| Net income growth (YoY) | 60.7% | 28.2% | 6.5% | - | -592.2% | -194.8% | - | - | - | 40.1% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | 40.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -67.0% | -58.9% | -41.9% | - | - | - | - | 9.6% | -93.2% | -22.8% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PLx Pharma Inc. against the 5 most active filers in the same SIC group.